Patients using long-acting GLP-1 injectables should focus on consistency and convenience rather than food timing when scheduling their injections
This rapid GSH loss disrupts redox homeostasis, promotes ROS accumulation, and facilitates redox-dependent protein modifications that drive apoptotic commitment
No office visit, no documentation, no video or telephone call
Noregain reflects normal homeostatic adaptation when appetite-suppressing medication stops
Novel GLP-1 agonist dulaglutide wins AWARD for type 2 diabetes AT THE ADA ANNUAL SCIENTIFIC SESSIONS CHICAGO Dulaglutide, an investigational once-weekly long-acting glucagonlike peptide1 receptor agonist, provided superior glycemic control compared with sitagliptin in patients with type 2 diabetes in the phase III AWARD-5 trial
High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial